• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·SMRUTHIORG.BO
Share

Smruthi Organics Limited Stocks

₹ 132.35Last Updated 21.10.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

₹ 17.72M

₹ 132.35
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Smruthi Organics Ltd. primarily focuses on the production and commercialization of bulk pharmaceutical ingredients and their chemical intermediates. The company's product range includes a variety of compounds such as amlodipine besilate, amisulpride, carbidopa, ciprofloxacin, diloxanide furoate, fenofibrate, metformin hydrochloride, norfloxacin, pefloxacin, telmisartan, amlodipine base, and phthaloyl amlodipine. This enterprise was established on July 11, 1989, by Purushotham Mallayya Eaga and is based in Solapur, India.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'che

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.10.2026 23:33

"Bullish sentiment evaporated overnight": Nasdaq fell 2.8% and is heading for its worst plunge since June

22.10.2026 22:26

Apple shares have become a "safe haven" amid concerns over AI spending. Should you buy them?

22.10.2026 21:37

Alibaba's stock has fallen the most in two months. What's weighing on it?

22.10.2026 20:57

Revolut has received its first credit rating. S&P anticipates the fintech company's entry into the bond market

22.10.2026 20:15

Meta's stock is heading for its worst day since July. Its credit risk has peaked due to AI spending

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026